Christopher Bunka
Director · Lexaria Bioscience Corp.
- 2025
- Mar 18, 2026
- 3
Other insiders active in the same stocks
Insiders who have reported open-market trades at the same companies as Christopher Bunka. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard Christopher - $132K in LEXX purchases and sales on record
- John Martin Docherty - $5K in LEXX purchases and sales on record
- William Edward McKechnie - $5K in LEXX purchases and sales on record
- Vanessa Carle - $683 in LEXX purchases and sales on record
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Bunka?
Christopher Bunka is a corporate insider, tracked as Director of Lexaria Bioscience Corp. (LEXX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Christopher Bunka last file a Form 4?
The most recent primary Form 4 on record is dated 18 March 2026, one of 3 filings going back to 2025.
Has Christopher Bunka been buying or selling stock?
Recorded transactions: 2 open-market purchases ($25K) and 0 open-market sales across all tracked filings.
